|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
2002-8-12
|
|
pubmed:abstractText |
CAMPATH-1 (CD52) Abs have been used in stem-cell transplants for the prevention of GvHD and graft rejection. These complications can effectively be prevented by depletion of T lymphocytes from both donor and recipient. However, donor lymphocytes might contribute an anti-leukemia effect and lymphocyte depletion may exacerbate problems with immune reconstitution. There is a fine balance between the risks of GvHD and host-versus-graft reactions, relapse and infection.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
1465-3249
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
3
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
145-64
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:12171722-Antibodies, Monoclonal,
pubmed-meshheading:12171722-Antibodies, Monoclonal, Humanized,
pubmed-meshheading:12171722-Antibodies, Neoplasm,
pubmed-meshheading:12171722-Clinical Protocols,
pubmed-meshheading:12171722-Clinical Trials as Topic,
pubmed-meshheading:12171722-Graft vs Host Disease,
pubmed-meshheading:12171722-Humans,
pubmed-meshheading:12171722-Immunosuppression,
pubmed-meshheading:12171722-Multicenter Studies as Topic,
pubmed-meshheading:12171722-Multivariate Analysis,
pubmed-meshheading:12171722-Patient Selection,
pubmed-meshheading:12171722-Stem Cell Transplantation,
pubmed-meshheading:12171722-T-Lymphocytes,
pubmed-meshheading:12171722-Treatment Outcome
|
|
pubmed:year |
2001
|
|
pubmed:articleTitle |
CAMPATH-1 antibodies in stem-cell transplantation.
|
|
pubmed:affiliation |
Sir William Dunn School of Pathology, University of Oxford, Oxford, UK.
|
|
pubmed:publicationType |
Congresses,
Research Support, Non-U.S. Gov't
|
